This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI), owing to its potential in the Peripheral Intervention arm and strong international foothold.
Pacific Biosciences (PACB) Down 10.8% Despite Narrower Q1 Loss
by Zacks Equity Research
Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.
Integer Holdings (ITGR) Loses 1.3% Despite Q1 Earnings Beat
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect weak segmental performance.
Hill-Rom (HRC) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Hill-Rom's (HRC) second-quarter revenues improved year over year on continued recovery across all three business segments as well as expanded demand for critical care products.
Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q1.
Merit Medical (MMSI) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 40.54% and 7.73%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Merit Medical (MMSI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dental Market Shows Strength Despite Pandemic: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on three lucrative stocks, XRAY, MCK and MMSI, in the dental space that have performed impressively despite the pandemic-led volatility.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to gain traction on a solid product portfolio and strong international exposure. However, stiff competition is worrisome.
Merit Medical (MMSI) Up 0.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.
Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 25.58% and 3.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.
Cardinal Health (CAH) Unveils New Logistics Management Tool
by Zacks Equity Research
Cardinal Health's (CAH) company, OptiFreight Logistics, launched TotalVue Analytics to help healthcare supply chain leaders to drive cost savings.
DENTSPLY (XRAY) Acquires Byte to Boost Clear Aligner Business
by Zacks Equity Research
DENTSPLY (XRAY) acquires Byte to strengthen presence in the lucrative clear aligner space.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and buyouts.
LabCorp's (LH) Covance Arm Stays Robust Amid Procedure Delay
by Zacks Equity Research
Apart from COVID-19 supports, LabCorp (LH) is making significant strides in other businesses.
Integra (IART) Sells Unprofitable Arm to Focus on Core Business
by Zacks Equity Research
Integra (IART) does not expect the selloff to have a material impact on its 2020 results.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Merit Medical Systems (MMSI) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Merit Medical Systems (MMSI) has been struggling lately, but the selling pressure may be coming to an end soon.
OPKO Health's (OPK) BioReference Starts Fan Testing Program
by Zacks Equity Research
OPKO Health's (OPK) BioReference commences mandatory, large-scale COVID-19 testing programs for fans for AFC Division Wild Card playoff game.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.
Here's Why You Should Hold on to Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vinci Surgical System. But weak operational performance is a woe.
Nevro's (NVRO) FDA Submission to Treat Patients With PDN
by Zacks Equity Research
Nevro's (NVRO) submission of a pre-market approval supplement to the FDA to seek approval for its Senza System can help in the treatment of chronic pain associated with PDN.